(Reuters) - The medicines -- Amgen's Aranesp and Epogen and J&J's Procrit -- had already been under considerable pressure as a raft of negative clinical news led to questions about their potential overuse and the possible harm they could be doing.
The cloud that got darker in March, when the U.S. Food and Drug Administration added new warnings to the drugs' labels, turned black on Thursday when the advisory panel came down hard on the marketing and use of the anemia drugs that had combined sales of $10 billion last year.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment